Pre-market Hot Trades in US Stocks
SCHMID Group NV pre-market rose 11.90%. Based on recent key news:
<ol>
<li>
On January 21, SCHMID Group NV announced that it would use the net proceeds from the investment agreement for general corporate purposes, including working capital, capital expenditures, and potential acquisitions or investments. This news drove the stock price up 4.35% in pre-market. Source: Company press release
</li>
<li>
On January 21, SCHMID Group NV has technology centers and manufacturing bases in Germany and China, and sales and service points in multiple locations worldwide. The company focuses on developing customized equipment and process solutions for various industries, including electronics, renewable energy, and energy storage. The enhancement of such technology and production efficiency has strengthened market confidence in its future development. Source: Company website
</li>
<li>
On January 21, SCHMID Group NV's systems and process solutions ensure the highest technical standards, high output, and low production costs, maximizing efficiency, quality, and sustainability. The advantages of these green production processes further consolidate its market position. Source: Company website Industry technological innovation drives stock price increase.
</li>
</ol>
Akanda pre-market fell 7.64%. Based on recent key news:
<ol>
<li>
On January 21, Akanda's technical signals indicated &#34;sell,&#34; coupled with a very small market capitalization, leading analysts to adjust their outlook. Akanda's market value is only $2.56 million, and the &#34;sell&#34; technical signal puts pressure on the stock price.
</li>
<li>
On January 21, HRT Financial LP reported the sale of Akanda's common stock, increasing the market's selling pressure on the company's shares. HRT Financial LP is a 10% shareholder of Akanda, and its selling behavior has intensified the stock price decline.
</li>
<li>
On January 20, Akanda released a statement regarding its shareholder structure, confirming HRT Financial LP as its 10% shareholder, which may affect investor confidence. The market is highly volatile for small-cap stocks.
</li>
</ol>
Top Gainers in Pre-market US Stocks
iOthree pre-market rose 189.08%. Based on recent key news:
<ol>
<li>
On January 20, iOThree Ltd. released an important announcement via GlobeNewswire, leading to a significant rise in stock price. The announcement detailed the company's recent strategic adjustments and market expansion plans, attracting strong investor attention and driving the stock price up 189.08% in pre-market.
</li>
<li>
On January 19, the market expressed optimism about iOThree's technological innovations and product launches. The company announced a new technological breakthrough expected to significantly enhance its market competitiveness, and investors reacted positively, further driving the stock price up.
</li>
<li>
On January 18, analysts gave a positive evaluation of iOThree's future growth potential. Several well-known brokerages released reports, believing that the company's expansion in emerging markets will bring considerable revenue growth, enhancing market confidence
The technology sector has recently performed strongly, with significant capital inflows.
</li>
</ol>
60 Degrees Pharmaceuticals is up 50.50% in pre-market trading. There are no significant news updates recently; trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows notable volatility, and specific reasons need further observation. no_news
Greenwich Lifesciences is up 49.33% in pre-market trading. Based on recent key news:
<ol>
<li>
On January 22, Greenwich Lifesciences announced that its breast cancer immunotherapy GLSI-100 received FDA manufacturing approval in the FLAMINGO-01 trial, driving the stock price up. The FDA approved the first GP2 drugs for the trial, and the stock price rose over 16% in pre-market trading. Source: GlobeNewswire
</li>
<li>
On January 22, the company released open-label Phase III data from FLAMINGO-01, showing nearly an 80% reduction in recurrence rates for non-HLA-A*02 group patients. This data is crucial for marketing applications to the FDA and overseas regulatory agencies. Source: GlobeNewswire
</li>
<li>
On January 22, the company plans to use the new GP2 vials at 40 sites in the U.S. in the coming weeks, with the CEO stating that production data will be submitted to regulatory agencies in Europe, the UK, and Canada. Source: GlobeNewswire The biotechnology sector has recently performed strongly, with significant capital inflows
</li>
</ol>

SHMD

AKAN

SCHMID Group NV pre-market up 11.90%; Akanda pre-market down 7.64%; iOthree pre-market up 189.08%; 60 Degrees Pharmaceuticals pre-market up 50.50%; Greenwich Lifesciences pre-market up 49.33%

Pre-market hot trades in the US stock market: SCHMID Group NV pre-market up 11.90%; Akanda pre-market down 7.64%